Upper respiratory tract infection

LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting

Retrieved on: 
Saturday, March 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Conditional sentence, University, Leo Pharma, BV, Aes, COVID-19, American Academy, Atopic dermatitis, Development, Dermatology, MD, Patient, AAD, LEO, American Academy of Dermatology, Cytokine, Upper respiratory tract infection, Safety, Pharmaceutical industry, EASI

LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
  • Results were shared as one of two LEO Pharma late breaker oral presentations at the 2023 American Academy of Dermatology (AAD) Annual Meeting.1 LEO 138559 is an investigational agent and its efficacy and safety are subject to further larger trials.
  • LEO Pharma and argenx BV jointly developed LEO 138559 under an exclusive option and research agreement.
  • LEO Pharma obtained the license to LEO 138559 in 2022 and now assumes the responsibility to develop and commercialize LEO 138559 for inflammatory skin disorders, such as atopic dermatitis.

Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

Retrieved on: 
Thursday, March 16, 2023
DSM-IV codes, LGG, Hospital for Sick Children (Toronto), Diarrhea, Progression-free survival, McKesson Corporation, Clinical trial, Hope, BRAF, Mutation, Research, Brain, Abdominal pain, PFS, BRAF V600, Lung, Rash, ASCO, Vomiting, Bleeding, Dizziness, American Society of Clinical Oncology, Novartis, MD, Patient, Melanoma, The Hospital, Annual general meeting, Nausea, St Saviour's and St Olave's Church of England School, FRCPC, Upper respiratory tract infection, Phase, FDA, Fever, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Thyroid cancer, ORR, Food, Fatigue, Medical imaging, Pharmaceutical industry, Dabrafenib

The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.

Key Points: 
  • The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.
  • These approvals make Tafinlar + Mekinist the first and only approved combination targeted therapy to treat pediatric patients with BRAF V600E LGG.
  • BRAF V600 mutations are present in 15-20% of pediatric LGGs and are associated with poor survival outcomes and less favorable response to chemotherapy4.
  • BRAF mutations have been identified as drivers of cancer growth across a wide range of solid tumors, and often have limited treatment options4,5.

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, February 21, 2023
Shoulder, Medicaid, Achilles tendon, Pregnancy, Diet, Moyamoya disease, State Administrative Expenses, Atrial fibrillation, MACE, Upper respiratory tract infection, Acceleration, Abdominal pain, PIN, Uric acid, Spasm, Pain, Simvastatin, Medicare, Hosting, Cholesterol, Patient, Pravastatin, Bronchitis, Back pain, Disease, Drug, Anemia, Lactation, Fetus, Sale, Health, Mortality, Cardiology, Gout, Risk, Congress, ESPR, Major adverse cardiovascular events, Treasury, CLEAR, Concentration ratio, Research, Cardiovascular disease, EmblemHealth, Kidney, Rotator cuff, Medical imaging, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Hyperuricemia, Tufts University, Esperies

ANN ARBOR, Mich., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • “I’m proud of the entire organization at Esperion and our ability to deliver on the commitments we made in 2022.
  • The increase for the fourth quarter ended December 31, 2022, is related to increases in net U.S. product revenue and royalty revenue.
  • These decreases reflect savings from the transformative plan implemented in the fourth quarter of 2021.
  • Esperion works hard to make our medicines easy to get, easy to take, and easy to have.

Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC

Retrieved on: 
Monday, February 20, 2023
Shoulder, Achilles tendon, Pregnancy, Diet, Moyamoya disease, Atrial fibrillation, Nissen, Upper respiratory tract infection, Abdominal pain, Uric acid, Spasm, Pain, Simvastatin, Patient, Pravastatin, Bronchitis, Back pain, Disease, Drug, Anemia, Heart, Lactation, Fetus, Health, Mortality, Gout, Risk, Cleveland Clinic, Rotator cuff, Esperies, Kidney, MD, Dietary supplement, Pharmaceutical industry, Hyperuricemia

Hyperuricemia may occur early in treatment and persist throughout treatment, and may lead to the development of gout, especially in patients with a history of gout.

Key Points: 
  • Hyperuricemia may occur early in treatment and persist throughout treatment, and may lead to the development of gout, especially in patients with a history of gout.
  • Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
  • Drug Interactions: Simvastatin and Pravastatin: Concomitant use results in increased concentrations and increased risk of simvastatin or pravastatin-related myopathy.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Retrieved on: 
Friday, February 10, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, South African Class MG 2-6-6-2, CK, Inflammation, Acne, Drug development, Abstract, Week, Upper respiratory tract infection, Safety, Patient, Common, Urinary tract infection, Associate, Hidradenitis suppurativa, JAK1, Autoimmunity, Conference, COVID-19, HS, Headache, Pharmaceutical industry, Abscess

Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).

Key Points: 
  • Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).
  • These data were presented as an oral presentation (Abstract #258) at the 12th Conference of the European Hidradenitis Suppurativa Foundation, held from February 8-10, 2023, in Florence, Italy.
  • Povorcitinib was generally well tolerated and the safety profile was consistent with previously-reported data.
  • We look forward to continuing to progress the development of povorcitinib through our ongoing Phase 3 trial in patients with moderate-to-severe HS.”
    Additional 52-week efficacy results include:

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Tuesday, February 7, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Chronic obstructive pulmonary disease, ECCMID, Human, Viral load, Fiscal, ICAR, Half-life, SARS-CoV-2, Epidemiology, PK, International Society for Antiviral Research, Omicron, Upper respiratory tract infection, Data, Virus, Viral, Animal, Safety, RSV, Patient, Asthma, Housing, Ritonavir, HBV, Risk, Virology, European Congress of Mathematics, Congress, Ferret, HCV, Heart, Infection, Research, International Conference on Emerging Infectious Diseases, Antiviral Research, Conference, European, Pharmacokinetics, Medication, Pharmaceutical industry, Cryptocurrency, Video game, Vaccine, Perfume, SPRINT

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022.
  • For the three months ended December 31, 2021, total royalty revenue was $27.6 million on AbbVie’s sales of MAVYRET/MAVIRET.
  • The decline is primarily a result of continued lower treated patient volumes due to the COVID-19 pandemic.
  • Research and development expenses totaled $40.9 million for the three months ended December 31, 2022, compared to $48.5 million for the three months ended December 31, 2021.

Worldwide Bovine Respiratory Disease Treatment Industry to 2030: North America Currently Dominates the Market - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
Infectious Diseases, Health, Veterinary, Farmer, Vaccine, Upper respiratory tract infection, Bovinae, Bovine respiratory disease, Vaccination, Meat, Lower respiratory tract infection, Cattle, Animal husbandry, Growth, Prevalence, Hospital, Infection, Livestock

Geographically, the global bovine respiratory diseases treatment market is cumulative to North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Key Points: 
  • Geographically, the global bovine respiratory diseases treatment market is cumulative to North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
  • Among the considered regional markets, North America currently dominates the global bovine respiratory disease treatment market, followed by Europe.
  • What are the key micro and macro environmental factors that are impacting the growth of Bovine Respiratory Disease Treatment market?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Bovine Respiratory Disease Treatment market worldwide?

Cystic Fibrosis Therapeutics Market Report 2023: Advancements in R&D Progress Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Medical Devices, Health, Stem Cells, Physical Therapy, Managed Care, Pharmaceutical, Distribution (marketing), Liver, Administration, Route of administration, Mucus, Chest infection, Upper respiratory tract infection, CF, Pulmonary function testing, IRT, Agent handling, Route, Medication, Patient, Inflammation, Chest pain, Project delivery method, Research, Gland, Pharmacy, Therapy, CFTR, Sodium, Inhalation, Gastrointestinal tract, Pancreas, Disease, US, Genetic, Medical device, Feces, Blood pressure, Dietary supplement, Pharmaceutical industry, Others, Growth, Perspiration, Cystic fibrosis, Hospital

Although clinically the least serious problem, increased sodium and chloride concentration in sweat is the undisputed hallmark of cystic fibrosis.

Key Points: 
  • Although clinically the least serious problem, increased sodium and chloride concentration in sweat is the undisputed hallmark of cystic fibrosis.
  • The outlook for cystic fibrosis has improved considerably in recent five years due to advancements in R&D of treatment, although most people with cystic fibrosis will have shorter-than-average life assurance.
  • On the Test Type segment, the Global Cystic Fibrosis Therapeutics Market has been differentiated into Pulmonary Function, Sweat, IRT, Fecal, and Genetic.
  • In addition, advanced experimental approaches have been established to accelerate the development of novel modulators, effectively boosting the Cystic Fibrosis Therapeutics Market.

Global Bovine Respiratory Disease Treatment Market 2022 to 2030: Players Include Bayer, Boehringer Ingelheim, Bimeda, Ceva and Elanco

Retrieved on: 
Thursday, January 26, 2023
Cattle, Pneumonia, Diphtheria, Bovine respiratory disease, Boehringer Ingelheim, Meat, Infection, Hospital, Vaccine, Growth, Bovinae, Lower respiratory tract infection, Prevalence, Farmer, Upper respiratory tract infection, Bayer, Vaccination, Merck & Co., Animal husbandry, Fine chemical, Livestock, Bimeda

This report presents and analyzes the major trends prevalent in the global bovine respiratory disease treatment market and the market size and forecast.

Key Points: 
  • This report presents and analyzes the major trends prevalent in the global bovine respiratory disease treatment market and the market size and forecast.
  • This report categorizes the global bovine respiratory disease treatment market in terms of treatment type, disease type, distribution channel and geographical distribution.
  • Based on treatment types, the global bovine respiratory disease treatment market is categorized into vaccines, antibiotics, immunomodulators and others.
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Bovine Respiratory Disease Treatment market worldwide?

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Friday, January 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, Infection, COPD, Upper respiratory tract infection, Pharmacokinetics, RSV, Urinary tract infection, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PK, COVID-19, Risk, Human, Animal, Medication, Ferret, Patient, Severe acute respiratory syndrome coronavirus 2, Chronic obstructive pulmonary disease, Safety, Degenerative disease, FDA, Webcast, HBV, Conference, Asthma, Virology, Fast Track, Heart, Pharmaceutical industry, Vaccine, SPRINT

In RSV, we continue to expect top-line data from the Phase 1 study of EDP-323, our L-protein inhibitor, in the first half of 2023.

Key Points: 
  • In RSV, we continue to expect top-line data from the Phase 1 study of EDP-323, our L-protein inhibitor, in the first half of 2023.
  • Enanta expects to report data from this Phase 2 study in the first half of 2023.
  • Enanta also today announced a new research program focused on the discovery and development of inhibitors of the SARS-CoV-2 PLpro for the oral treatment of COVID-19.
  • A replay of the webcast will be available following the presentation and will be archived for approximately 60 days.